{"id":76680,"date":"2026-08-26T13:02:06","date_gmt":"2026-08-26T05:02:06","guid":{"rendered":"https:\/\/flcube.com\/?p=76680"},"modified":"2026-08-26T13:02:07","modified_gmt":"2026-08-26T05:02:07","slug":"fda-approves-beones-tevimbra-plus-zanidatamab-and-chemotherapy-for-first-line-her2-positive-gastroesophageal-adenocarcinoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76680","title":{"rendered":"FDA Approves BeOne’s Tevimbra Plus Zanidatamab and Chemotherapy for First\u2011Line HER2\u2011Positive Gastroesophageal Adenocarcinoma"},"content":{"rendered":"\n

BeOne Medicines Ltd. (NASDAQ: ONC<\/a>; HKG: 6160<\/a>; SHA: 688235<\/a>)<\/strong> announced that the US FDA<\/strong> has approved the fourth indication<\/strong> for Tevimbra (tislelizumab)<\/strong>, in combination with zanidatamab<\/strong> and chemotherapy, for the first\u2011line treatment<\/strong> of adult patients with locally advanced unresectable or metastatic HER2\u2011positive gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA)<\/strong>. The approval establishes a new immuno\u2011targeted combination backbone in one of the most treatment\u2011challenging oncology settings.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>US FDA<\/td><\/tr>
Approval Date<\/strong><\/td>26 Aug 2026<\/td><\/tr>
Product<\/strong><\/td>Tevimbra (tislelizumab) + zanidatamab + chemotherapy<\/td><\/tr>
Indication<\/strong><\/td>First\u2011line locally advanced unresectable or metastatic HER2\u2011positive gastroesophageal adenocarcinoma (GEA)<\/td><\/tr>
Significance<\/strong><\/td>Fourth approved indication for Tevimbra in the US<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile & Mechanism of Action<\/h2>\n\n\n\n